Biofortuna, a specialist contract development and manufacturing partner to the IVD and point-of-care testing sectors, has more than doubled its manufacturing capacity following relocation to new state-of-the-art facilities on Deeside, North Wales.
The purpose-built facilities have been designed by the company to provide the most efficient and modern manufacturing laboratories from which to meet the evolving needs of the world’s leading IVD and point-of-care businesses.
Dr Nick Ash, Biofortuna Chief Executive Officer, commented "This multimillion-pound investment demonstrates our ambition and commitment to become the sectors’ leading support specialist, helping our customers to accelerate their diagnostic development programmes from concept to commercialisation."
Paul Williams, Head of Sales, added "This facility will position Biofortuna as one of the leading outsourced providers of genomic services, custom assay development and contract manufacturing. It has been designed to expand our turn-key capabilities and provide our customers with a scalable resource to develop and manufacture their assays, particularly in the point-of-care and decentralised IVD testing space."